Injectable anabolic androgenic steroid
Drostanolone Enanthate (Masteron Enanthate)
Drostanolone Enanthate (Masteron Enanthate) after one dose: 50% at ~7.5 days, 25% at 15 days, 12.5% at 22.5 days.
Drawn from the half-life in the app's model, ~7.5 days. The model's figures
- Compound
- Drostanolone Enanthate (Masteron Enanthate)
- Symbol
- MSE
- Family
- Other steroids
- Parts
- 14
- References
- 18
- Checked
- Last reviewed . Sources are listed below.
How Milligram users log it

4%The joint 16th most tracked compound in Milligram: of people who track compounds in Milligram logged Drostanolone Enanthate (Masteron Enanthate) in the last 90 days.
Schedule
Logged doses
Half of people logged between 50 and 200 mg per dose; the median was 100 mg.
Tracked alongside
The share of people logging Drostanolone Enanthate (Masteron Enanthate) who also logged each.
From dose logs in the Milligram app, 90 days to 15 November 2026. Aggregated and anonymous. This describes what people recorded, not what anyone should take.
Overview
Drostanolone is an anabolic androgenic steroid, listed in the US Schedule III entry as 17β-hydroxy-2α-methyl-5α-androstan-3-one.1,2 Drostanolone enanthate appears in the studies below as an expected compound in four tested samples, as a compound detected in two raw powders, as a compound found in head hair, and as the starting compound of a 2017 laboratory study.3,4,5,6
A 2021 review by Tauchen and colleagues in Molecules describes drostanolone as "another agent that has been removed from medicinal use, although it was of value in certain types of breast cancer", and its table lists the breast cancer use as "now discontinued in most countries".7 The review's table lists the propionate ester of drostanolone as an intramuscular injection.7 None of the sources cited below is a drug label for a drostanolone product.
The Moderate Evidence badge shown with this compound is the app's own grade and not a conclusion of the sources. The human trials cited below date from 1975 to 1982 and name drostanolone, dromostanolone or drostanolone propionate rather than the enanthate, and their PubMed records report no half-life, bioavailability or time to peak.8,9,10,11,12
How it works
Sources in this part
Tauchen and colleagues write that "every anabolic steroid retains some androgenic activity" and name a methyl group at the C2 position, as in drostanolone, among the changes that may increase anabolic activity.7 De Boer and colleagues, in the Journal of Steroid Biochemistry and Molecular Biology in 1992, group drostanolone with mesterolone as a methyl-5 alpha-dihydrotestosterone and give its structure as 2 alpha-methyl-17 beta-hydroxy-5 alpha-androstan-3-one.13 They report 2 alpha-methyl-androsterone as the major metabolite of drostanolone in urine and state that "all metabolites were found to be conjugated to glucuronic acid".13 Liu and colleagues, in Steroids in 2016, gave drostanolone to one healthy male volunteer and confirmed eleven metabolites: five new sulfates, five glucuronide conjugates and one free metabolite.14 Three of the five authors are at the National Anti-Doping Laboratory of the China Anti-Doping Agency, and the PubMed record is tagged "Research Support, Non-U.S. Gov't" and names no funder.14
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~7.5 days
- Bioavailability
- 95%
- Typical dose
- 150–500 mg/week
- Route
- IM
- Time to peak
- ~48 h
Sources in this part
The app's figures for drostanolone enanthate are a half-life of ~7.5 days (180 hours), a bioavailability of 95%, a time to peak of ~48 h, an intramuscular route and a typical dose of 150–500 mg/week. None of the sources cited below reports a half-life, bioavailability, time to peak or dose for the enanthate, as the table shows.
| Measure | App figure | Source figure |
|---|---|---|
| Half-life | ~7.5 days (180 h) | None of the cited sources reports a half-life for drostanolone enanthate. After intramuscular injection of drostanolone to one healthy male volunteer, two metabolites proposed as biomarkers were detectable for up to 24 days by liquid-liquid extraction and 7 days by direct-injection analysis (detection windows, not a half-life), and the PubMed record does not name the ester or state the dose given.14 |
| Bioavailability | 95% | None of the cited sources reports a bioavailability for drostanolone enanthate. |
| Time to peak | ~48 h | None of the cited sources reports a time to peak for drostanolone enanthate. |
| Route | IM | None of the cited sources gives a route for drostanolone enanthate. The Liu volunteer study used intramuscular injection of drostanolone, and the 2021 review lists the propionate ester of drostanolone as an intramuscular injection.14,7 |
| Typical dose | 150–500 mg/week | None of the cited sources gives a dose for drostanolone enanthate, and the two product tests below report concentrations and purity rather than doses. |
What tested samples contained
Deeper analysis: Piatkowski and colleagues, Harm Reduction Journal, 2025
Piatkowski and colleagues (Griffith University in Queensland, Australia, and other affiliations) tested anabolic steroid samples that community members submitted to two drug-checking sites between 19 April and 16 August 2024.3 Direct mass spectrometry (Radian-ASAP) and liquid chromatography mass spectrometry (Orbitrap) checked identity and dosage, and of 46 analysable samples 9 had presence issues (the compound differed from expectations) and 15 had purity issues (the concentration was too low or too high), with 36 samples analysed for concentration.3 The paper's results table lists four samples with the expected compound Drostanolone Enanthate (Masteron) at an expected 200 mg/mL, and in all four the compound detected was drostanolone enanthate.3
| Sample | Expected | Measured | Concentration as expected? |
|---|---|---|---|
| Sample 1, wave 1 (19 April to 7 June 2024) | 200 mg/mL | 215 mg/mL (± 5% error range 204–226) | No, overdosed |
| Sample 2, wave 1 | 200 mg/mL | 201 mg/mL (± 5% error range 191–211) | Yes |
| Sample 3, wave 1 | 200 mg/mL | 203 mg/mL (± 5% error range 193–213) | Yes |
| Sample 4, wave 2 (14 June to 16 August 2024) | 200 mg/mL | 257 mg/mL (± 5% error range 244–270) | No, overdosed |
Sources in this part
The study was funded by the Queensland Mental Health Commission.3 Several authors declare that they are volunteer members of The Loop Australia, "a national organisation for drug checking and drug checking research", and one author is its chief executive.3 On limitations, the authors write that their "testing approach evolved considerably from Wave 1 to Wave 2" and that in Wave 1 "purity analysis was limited, with only one sample undergoing such assessment", after which they "re-analysed all Wave 1 samples alongside newly collected ones".3 The samples were community-submitted, as the paper's own description of its design states.3
Deeper analysis: Craven and colleagues, Drug and Alcohol Review, 2025
Craven and colleagues analysed 28 anonymously donated samples (16 injectable, 10 oral, 2 raw powders) at an independent forensic laboratory using gas chromatography–mass spectrometry, liquid chromatography–mass spectrometry and inductively coupled plasma analysis, and reported that 15 samples were mislabelled or mis-sold.4 Two raw powders expected to be testosterone enanthate each contained, according to the paper's table, testosterone without ester, androstenedione, testosterone valerate, methandriol, drostanolone enanthate and another unidentified steroid compound, listed against a labelled dosage of 100% with a purity range of 87.0%–96.9% (91.9 ± 3.2).4 The testing was funded by PEDTest Australia, a private business that provides reagent testing kits and is led by an author of the paper, who is its chief executive.4 The authors state that "the small sample size, while significant, may not be representative of the broader Australian AAS market" and that the study covered products collected from 2022 to 2024.4
Human studies
The human studies below used drostanolone, dromostanolone or drostanolone propionate in breast cancer or aplastic anemia, and none names the enanthate.8,9,10,11,12
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Rieche and Wolff, 19758 | Randomised clinical study of single hormone therapy, then with cyclophosphamide added. | Patients with disseminated (metastatic) breast cancer; number not given in the PubMed record. | Doses not given in the PubMed record; observation period of 10 to 16 weeks. | Testosterone decanoate, drostanolone and testosterone gave similar rates of objective responses; with cyclophosphamide, testosterone decanoate and testolactone had more beneficial effects than drostanolone, and the combination raised objective responses from 22-25 percent to 46-55 percent. |
| Wolff and Rieche, 19789 | Controlled clinical trial comparing testololactone, drostanolone and nandrolone; cyclophosphamide added after 4 weeks. | 91 patients with advanced breast cancer. | Doses not given in the PubMed record; remissions registered after 4 weeks and after another 12 weeks. | No difference in effectivity between the three drugs; average remission rate 24% after 4 weeks and 46% after 16 weeks, the second interval including cyclophosphamide. |
| Bennett and colleagues, 197510 | Trial from 1968 to 1972 of drostanolone propionate (Masteril) against oophorectomy, nandrolone phenylpropionate or ethinyl oestradiol, by menopausal group. | Patients with breast cancer in premenopausal, perimenopausal and postmenopausal groups; numbers not given in the PubMed record. | Doses and length not given in the PubMed record. | Response 44% with drostanolone propionate against 22% with oophorectomy (premenopausal); 34.5% against 39% with nandrolone phenylpropionate (perimenopausal); 38.5% against 57% with oestrogens (postmenopausal). |
| Clavel and colleagues, 198211 | Randomised trial of hormonal therapy, CMF chemotherapy or both. | 98 post-menopausal women with breast cancer; hormone receptors not assayed in any patient. | Tamoxifen and drostanolone propionate (n = 34), CMF chemotherapy (n = 30) or both (n = 34); doses and length not given in the PubMed record. | The authors report results in favour of hormonal therapy alone, with the best immediate objective responses, the least adverse side-effects and possibly improved survival rates; rates are not given in the PubMed record. |
| Azen and Shahidi, 197712 | Case reports. | Three patients with acquired aplastic anemia are described; dromostanolone is reported in two patients. | Doses not given in the PubMed record. | No hematologic response to dromostanolone in two patients; blood counts correlated with oxymetholone dosage in the three patients described. |
Deeper analysis: Rieche and Wolff, 1975, and Wolff and Rieche, 1978
Rieche and Wolff, in Archiv fur Geschwulstforschung in 1975, report a randomised study in metastatic breast cancer in which, in the authors' words, single hormone therapy with testosterone decanoate, drostanolone and testosterone "gave similar rates of objective responses".8 Adding cyclophosphamide raised objective responses from 22-25 percent to 46-55 percent, and over 10 to 16 weeks testosterone decanoate and testolactone with cyclophosphamide had more beneficial effects than drostanolone with cyclophosphamide.8 Wolff and Rieche, in Onkologie in 1978, compared testololactone, drostanolone and nandrolone in 91 patients and report no difference between the three drugs, with an average remission rate of 24% after 4 weeks and 46% after 16 weeks, the second interval including cyclophosphamide.9 The PubMed records of both papers carry no funding statement, no statement of author ties and no stated limitations, and neither gives doses; the 1975 record also gives no patient number.8,9
Deeper analysis: Clavel and colleagues, 1982
Clavel and colleagues, in La Semaine des Hopitaux in 1982, randomised 98 post-menopausal women with breast cancer to tamoxifen and drostanolone propionate (n = 34), CMF chemotherapy (n = 30) or both (n = 34).11 They state that "hormonal receptors had not been assayed in any patient" and that the results "are in favour of hormonal therapy alone", which gave the best immediate objective responses, the least adverse side-effects and possibly improved survival rates.11 The hormonal arm combined tamoxifen with drostanolone propionate, so the result does not isolate drostanolone, and the PubMed record gives no response rates, funding statement or stated limitations.11
Deeper analysis: Bennett and colleagues, 1975
Bennett, Helman and Palmer, in the South African Medical Journal in 1975, tested drostanolone propionate (Masteril) between 1968 and 1972 against oophorectomy in premenopausal patients, against nandrolone phenylpropionate in a perimenopausal group and against ethinyl oestradiol in a postmenopausal group.10 The authors conclude that the drug "may appear to be less effective than oestrogens in the postmenopausal patients".10 The PubMed record gives no group sizes, doses, funding statement or stated limitations.10
What the sources say about side effects
Bennett and colleagues state that "the side-effects of Masteril are generally not serious and rarely contra-indicate its use", in a trial of drostanolone propionate in breast cancer.10 The PubMed record lists no individual side effects or rates.10 Clavel and colleagues report the least adverse side-effects in the hormonal arm (tamoxifen with drostanolone propionate) compared with chemotherapy or the combination, without giving rates in the PubMed record.11
Case reports with several steroids
Gheddar and colleagues, in the Journal of Analytical Toxicology in 2023, describe a 29-year-old man found dead at home, with anabolic tablets, oily solutions and syringes at the scene and an unremarkable autopsy.5 Head hair segments showed drostanolone (112-30 pg/mg), drostanolone enanthate (26-5 pg/mg) and drostanolone propionate (15-4 pg/mg) alongside testosterone, testosterone propionate, testosterone isocaproate, nandrolone decanoate, boldenone, stanozolol and trenbolone.5 The experts concluded that "the manner of death can be listed as toxic due to massive repetitive use of anabolic steroids during the previous months", a conclusion about the whole combination and not about drostanolone enanthate alone.5 The report describes one person, and the PubMed record carries no funding or conflict statement.5 Favretto and colleagues, in Drug Testing and Analysis in 2022, report a young man found dead on a hotel bed the day before a bodybuilding competition, with cardiomegaly and organ congestion at autopsy, clenbuterol in blood and urine (1 ng/ml each), and drostanolone's main metabolite, 2 alpha-methyl-androsterone, in urine (202 ng/ml).15 The authors identified "the abuse of doping substances as the underlying cause of death", again a conclusion about several substances and not about drostanolone alone.15 The authors write of "toxic levels of clenbuterol in blood", and the paper's text carries no funding or conflict statement.15
Markers and detection in testing
The app lists total testosterone, free testosterone, estradiol, hematocrit, lipids and PSA as markers to monitor for drostanolone enanthate. No cited source reports a change in any of them attributed to drostanolone enanthate. Gheddar and colleagues report blood testosterone of 4 ng/mL in a man whose hair held drostanolone enanthate,5 and Favretto and colleagues report an increased urinary testosterone/epitestosterone ratio of 11 in a man with a drostanolone metabolite in urine, each in one person with several steroids detected.15 In Liu and colleagues' volunteer study, two metabolites, S4 (2α-methyl-5α-androstan-17-one-6β-ol-3α-sulfate) and G1 (2α-methyl-5α-androstan-17-one-3α-glucuronide), were proposed as biomarkers of drostanolone misuse, detectable for up to 24 days by liquid-liquid extraction and 7 days by direct injection after intramuscular injection, and both were also found in two drostanolone-positive routine urine samples.14 Kintz and colleagues, in the Journal of Forensic Sciences in 2021, report drostanolone at 8 and 11 pg/mg in nail clippings among six authentic cases of abuse, and write that concentrations "were always in the low pg/mg range".16 They state that the detection window in nail is generally 3-8 months for fingernails and 4-12 months for toenails, a general statement and not one measured for drostanolone.16
Regulatory and anti-doping status
The World Anti-Doping Agency's 2026 Prohibited List, in force from 1 January 2026, places anabolic agents under S1 as "prohibited at all times" and names drostanolone among the anabolic androgenic steroids in S1.1 "when administered exogenously", and it does not name an ester of drostanolone.1 The list states that all prohibited substances in the class are non-Specified Substances.1 In the United States, 21 CFR 1308.13(f) places substances meeting the anabolic steroid definition in Schedule III, "including its salts, esters and ethers", and lists drostanolone as item (28), unless specifically excepted or listed in another schedule.2 A 1995 Flemish doping-control report lists drostanolone among mostly injectable steroids administered from 1990 on, and a 2025 Swedish laboratory survey lists it among the most common steroids detected, and neither names an ester.17,18 Delbeke and colleagues, in the International Journal of Sports Medicine in 1995, report that in some Flemish bodybuilding federations between 38 and 58% of the athletes controlled in 1988-1993 were found positive, a figure for doping agents as a group and not for drostanolone alone.17 Bohlin and colleagues, in Drug Testing and Analysis in 2025, analysed 21,172 consecutive analyses from routine AAS testing from 2014 to 2023 at a Swedish drugs-of-abuse laboratory, with 6% to 11% reported AAS-positive each year, and declare no conflicts of interest.18
What is not known
Sources in this part
- The half-life, time to peak and bioavailability of drostanolone enanthate are not reported in the sources cited above.
- None of the sources cited above compares drostanolone enanthate with drostanolone propionate.
- None of the cited trials gives a dose or schedule for drostanolone enanthate, and the two product tests report concentrations and purity rather than doses.3,4
- The laboratory study cited that starts from drostanolone enanthate, by Choudhary and colleagues in Frontiers in Pharmacology in 2017, made eight metabolites with two fungi and tested the compounds on four human cancer cell lines and a normal cell line.6
- Against HeLa cells the starting compound had an IC50 of 54.7 ± 1.6 μM, against PC-3 cells 96.2 ± 3.0 μM and against HCT116 cells 3.1 ± 3.2 μM, with no cytotoxicity against 3T3 normal cells, and the authors call it an "anti-cancer steroid"; these are cell results, not results in people.6
Frequently asked questions
What is the half-life of drostanolone enanthate?
The app gives drostanolone enanthate a half-life of ~7.5 days (180 hours). None of the cited sources reports a half-life for the enanthate; in one volunteer given drostanolone by intramuscular injection, two metabolites were detectable for up to 24 days by liquid-liquid extraction and 7 days by direct-injection analysis, which are detection windows and not a half-life.14 The PubMed record does not state the dose or the ester given.
Is drostanolone enanthate banned by WADA?
Drostanolone is named on the WADA 2026 Prohibited List among the anabolic androgenic steroids in S1.1 "when administered exogenously", and anabolic agents are prohibited at all times; the list names drostanolone and does not name an ester of it.1
Is drostanolone enanthate a controlled substance in the US?
Drostanolone is listed in 21 CFR 1308.13(f) among the Schedule III anabolic steroids, and the entry covers the listed substances "including its salts, esters and ethers", unless specifically excepted or listed in another schedule.2
What is Masteron enanthate?
Masteron is the name entered with drostanolone enanthate in the paper's table for four samples tested in Queensland in 2024, where the expected compound is "Drostanolone Enanthate (Masteron)" at an expected 200 mg/mL.3
How long is drostanolone detectable in urine?
In one healthy male volunteer given drostanolone by intramuscular injection, two proposed biomarker metabolites were detected for up to 24 days by liquid-liquid extraction and 7 days by direct-injection analysis.14 The PubMed record does not state the dose or name the ester given.
What did tests of samples expected to be drostanolone enanthate find?
In a 2024 Queensland drug-checking study, all four community-submitted samples expected to be drostanolone enanthate at 200 mg/mL contained drostanolone enanthate, measured at 215, 201, 203 and 257 mg/mL, with the paper marking the 215 and 257 mg/mL samples as overdosed.3 In a separate analysis of 28 Australian samples, funded by a business led by one of its authors, two raw powders expected to be testosterone enanthate also contained drostanolone enanthate, and the authors write that the sample "may not be representative of the broader Australian AAS market".4
Was drostanolone used as a medicine?
A 2021 review states that drostanolone "has been removed from medicinal use, although it was of value in certain types of breast cancer", and its table lists the breast cancer use as "now discontinued in most countries".7 Trials from 1975 to 1982 used drostanolone or drostanolone propionate in breast cancer.8,10,11
What side effects are reported for drostanolone?
No cited source lists individual side effects or rates for drostanolone. A 1975 trial of drostanolone propionate states that its side-effects "are generally not serious and rarely contra-indicate its use".10 Two case reports of deaths involve drostanolone together with other steroids, so neither attributes the death to drostanolone alone.5,15
Is drostanolone enanthate the same as drostanolone propionate?
Guides, tools and comparisons
References
- World Anti-Doping Agency. World Anti-Doping Code International Standard Prohibited List 2026. In force 1 January 2026. WADA Prohibited List 2026
- US Drug Enforcement Administration. 21 CFR 1308.13, Schedule III. Electronic Code of Federal Regulations. 21 CFR 1308.13
- Piatkowski T, Coomber R, Francis C, et al. Anabolic-androgenic steroid testing as a tool for consumer engagement and harm reduction: a sequential explanatory mixed-method study. Harm Reduct J 2025. PMC12231991
- Craven A, Ferris J, Nielsen S, Piatkowski T. Lead Astray? The Hidden Contaminants in Australian Anabolic-Androgenic Steroid Market and Their Potential Health Impact. Drug Alcohol Rev 2025. PMC12405805
- Gheddar L, Blanchot A, Ameline A, et al. The Power of Keratinous Matrices (Head Hair, Body Hair and Nail Clippings) Analysis in a Case of Death Involving Anabolic Agents. J Anal Toxicol 2023. PMID 36516229
- Choudhary MI, Siddiqui M, Atia-Tul-Wahab, et al. Bio-Catalytic Structural Transformation of Anti-cancer Steroid, Drostanolone Enanthate with Cephalosporium aphidicola and Fusarium lini, and Cytotoxic Potential Evaluation of Its Metabolites against Certain Cancer Cell Lines. Front Pharmacol 2017. PMID 29326586
- Tauchen J, Jurasek M, Huml L, Rimpelova S. Medicinal Use of Testosterone and Related Steroids Revisited. Molecules 2021. PMC7919692
- Rieche K, Wolff G. Comparison of testosterone decanoate, drostanolone and testololactone in disseminated breast cancer: a randomized clinical study. Arch Geschwulstforsch 1975. PMID 1243528
- Wolff G, Rieche K. Androgen therapy of incurable breast neoplasms. Controlled clinical study: nandrolone-testololactone-drostanolone. Onkologie 1978. PMID 362297
- Bennett MB, Helman P, Palmer P. Hormonal therapy of breast cancer with special reference to Masteril therapy. S Afr Med J 1975. PMID 1242823
- Clavel B, et al. Management of advanced breast cancer in post-menopausal women. A comparative trial of hormonal therapy, chemotherapy, and a combination of both. Sem Hop 1982. PMID 6293073
- Azen EA, Shahidi NT. Androgen dependency in acquired aplastic anemia. Am J Med 1977. PMID 578075
- de Boer D, de Jong EG, Maes RA, van Rossum JM. The methyl-5 alpha-dihydrotestosterones mesterolone and drostanolone; gas chromatographic/mass spectrometric characterization of the urinary metabolites. J Steroid Biochem Mol Biol 1992. PMID 1606052
- Liu Y, Lu J, Yang S, Zhang Q, Xu Y. New drostanolone metabolites in human urine by liquid chromatography time-of-flight tandem mass spectrometry and their application for doping control. Steroids 2016. PMID 26826321
- Favretto D, Stocchero G, Pertile R, et al. Post-mortem investigation into a death involving doping agents: The case of a body builder. Drug Test Anal 2022. PMC9804486
- Kintz P, Gheddar L, Raul JS. Testing for anabolic steroids in human nail clippings. J Forensic Sci 2021. PMID 33885144
- Delbeke FT, Desmet N, Debackere M. The abuse of doping agents in competing body builders in Flanders (1988-1993). Int J Sports Med 1995. PMID 7713634
- Bohlin KP, Villen T, Hopcraft O, Pohanka A, Ekstrom L. Prevalence of AAS-Positive Samples at Drug Abuse Laboratory Sweden Between 2014 and 2023 and Sub-Study of Dual Use of AAS and Narcotics. Drug Test Anal 2025. PMID 40992881